<!DOCTYPE html>
<html lang="en">

<head>

<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1">
<meta name="author" content="Peter Cartier"/>

<!-- START UPDATE -->
<meta name="description" content="Private Equity Valuation">
<title>Private Equity Valuation</title>
<!-- END UPDATE -->

<link rel="shortcut icon" type="image/png" href="/favicon.png">
<link rel="stylesheet" type="text/css" href="/_ass/v1/css/main.css">

</head>

<body id="post">

<header>

<a id="logo" href="/"><h1>Private Equity Blog</h1></a>
<div class="motto">The formulas, tricks and trade secrets of Private Equity</div>

</header>

<!-- START UPDATE -->
<section>
    <h1>Private Equity Valuation</h1>
    <h3>Sample Chapter</h3>
    <div class="postframe">
        <div class="postimage"></div>
        <div class="posttext"><p>This post follows on from these previous posts:</p><ul><li>What&#8217;s the deal with capex anyway?</li><li>Free cashâ€¦ flow, a primer</li><li>The free cash flow capex conundrum</li></ul><p>In all of my posts about FCF, I haven&#8217;t yet mentioned why investment bankers and private equiteers don&#8217;t use FCF in private equity valuation practice. Well, <strong>FCF is still too &#8220;bottom line&#8221; for business valuation</strong>. It includes taxes and, depending on what version you use (there&#8217;s FCF, FCFE &amp; FCFF), it can still be swayed by capital structure. This is why good ol&#8217; EBITDA still forms the basis of most valuations.</p><p>However, EBITDA isn&#8217;t the perfect measure for private equity valuation either; it is still an accounting construct. The advantage of EBITDA over FCF/FCFE/FCFF is that it is independent of depreciation, cost of capital (such as interest on debt) and taxes. <strong>The disadvantage of EBITDA is that it doesn&#8217;t account for capex, which is a vital driver to ongoing earnings. </strong>The other difference compared to FCF, is that EBITDA still includes accrued debtors and creditors. However, for the purpose of business valuation, this is a better representation of the future (as long as there&#8217;s no fraudulent manipulation) because accrual accounting is forward looking.</p><p>The implication of the capex omission (from EBITDA in a private equity valuation) is that the EBITDA of one business doesn&#8217;t compare well to the EBITDA of another business; the reason being that each may have different capex profiles. In a previous post, I explained that <strong>we can&#8217;t just use historical capex to adjust FCF (or in this case EBITDA), because it usually contains one-off items. </strong>So, what many people do is use EBIT as their earnings proxy and for private equity valuations because it accounts for capex via depreciation (the argument being that depreciation is a good proxy for capex). Of course, this is fraught with danger because the past isn&#8217;t the future and the future isn&#8217;t the past. If anything, most businesses will spend more on capex than they depreciate as they grow and enter different industries.</p><p>Unfortunately, the solution isn&#8217;t so simple. In my opinion, <strong>the best earnings measure to use for business valuation is a maintainable and forward-looking EBITDA figure adjusted for the capex required to operate the business under normal conditions</strong>. Most of the work will probably go into understanding the real capex position of the business, but at least you can sleep well knowing you&#8217;ve invested on robust, rigorous and realistic analysis. So just to recap, the potential measure for earnings when calculating value includes:</p><ul><li><strong>NPAT </strong>- almost never used, too &#8220;bottom line&#8221; and a pure accounting construct</li><li><strong>FCF </strong>- still too &#8220;bottom line&#8221;, capex is often backward looking, rarely used in valuation</li><li><strong>EBITDA </strong>- ignores capex, which is an absolute sin, but this measure is commonly used</li><li><strong>EBIT </strong>- ignores the evolving nature of capex, sometimes used, 2nd best of many bad options</li><li><strong>EBIT-DAC </strong>- can still be manipulated by accruals, but the best of a bad lot</li></ul><p>For the record, in Europe, <strong>EBITDA minus capex is denoted as EBIT-DAC or EBITDAC</strong>.</p>
</div>
    </div>
    <div class="more">Read all of this and more in the 200+ page book. See below.</div>
    <div class="book">
        <img class="cover" src="http://www.theprivateequiteer.com/wp-content/themes/tpe/images/book-cover.png" alt="Private Equity" />
        <div class="blurb">
            <h2>Get the eBook Here <span>&rarr;</span></h2>
            <p>A 200+ page PDF eBook exploring the formulas, tricks and trade secrets of private equity. <strong>Only $39</strong></p>
        </div>
        <div class="buy">
            <a href="https://theprivateequiteer.dpdcart.com/cart/buy?product_id=125929&product_price_id=134201&gateway=creditcard" onclick="_gaq.push(['_trackPageview', 'book/buy_now']);"><img src="http://www.theprivateequiteer.com/wp-content/themes/tpe/images/buy-button.png" alt="Private Equity Guide" /></a>
            <p>Secure payment via Stripe</p>
        </div>
    </div>
</section>
<aside id="side">
    <h3>Topics</h3>
    <ul>
        <li><a href="/category/analysis-dd/">Analysis &amp; DD</a></li>
        <li><a href="/category/anti-pe/">Anti-PE</a></li>
        <li><a href="/category/banks-debt/">Banks &amp; Debt</a></li>
        <li><a href="/category/dealmaking/">Dealmaking</a></li>
        <li><a href="/category/entrepreneur/">Entrepreneur</a></li>
        <li><a href="/category/firm-fund/">Firm &amp; Fund</a></li>
        <li><a href="/category/private-equiteers/">Private Equiteers</a></li>
        <li><a href="/category/structuring/">Structuring</a></li>
        <li><a href="/category/theories-ideas/">Theories &amp; Ideas</a></li>
        <li><a href="/category/valuation/">Valuation</a></li>
    </ul>
    <h3>Technical</h3>
    <ul>
        <li><a href="/bolt-on-acquisitions/">Bolt-On Acquisitions</a></li>
        <li><a href="/business-valuation/">Business Valuation</a></li>
        <li><a href="/capital-expenditure-capex/">Capital Expenditure</a></li>
        <li><a href="/carried-interest-private-equity/">Carried Interest</a></li>
        <li><a href="/equity-clawback/">Clawback</a></li>
        <li><a href="/private-equity-deal-killers/">Deal Killers</a></li>
        <li><a href="/debt-covenants/">Debt Covenants</a></li>
        <li><a href="/due-diligence/">Due Diligence</a></li>
        <li><a href="/earnout-earn-out/">Earnout</a></li>
        <li><a href="/ebitda-vs-ebit/">EBITDA vs EBIT</a></li>
        <li><a href="/earnings-multiple-valuation-method/">Earnings Multiple</a></li>
        <li><a href="/equity-ratchet/">Equity Ratchet</a></li>
        <li><a href="/exit-strategies-private-equity-funds/">Exit Strategies</a></li>
        <li><a href="/free-cash-flow-analysis/">Free Cash Flow</a></li>
        <li><a href="/general-partner">General Partner</a></li>
        <li><a href="/j-curve-private-equity-101/">J-Curve</a></li>
        <li><a href="/leveraged-buyout-private-equity/">Leveraged Buyout</a></li>
        <li><a href="/limited-partner/">Limited Partner</a></li>
        <li><a href="/listed-private-equity/">Listed PE</a></li>
        <li><a href="/management-buyout-private-equity/">Management Buyout</a></li>
        <li><a href="/mergers-acquisitions-private-equity/">Mergers & Acquisitions</a></li>
        <li><a href="/middle-market-private-equity/">Middle Market</a></li>
        <li><a href="/preference-shares/">Preference Shares</a></li>
        <li><a href="/preferred-stock/">Preferred Stock</a></li>
        <li><a href="/recapitalization-recap/">Recapitalization</a></li>
        <li><a href="/team-dynamics-private-equity-firms/">Team Dynamics</a></li>
        <li><a href="/trade-deal-vs-private-equity-deal/">Trade Deals</a></li>
        <li><a href="/business-valuation/">Valuation Methods</a></li>
        <li><a href="/vendor-finance-private-equity/">Vendor Finance</a></li>
        <li><a href="/calculate-working-capital/">Working Capital</a></li>
    </ul>
    <h3>Contact</h3>
    <ul>
        <li><a href="mailto:&#098;&#108;&#111;&#103;&#064;&#116;&#104;&#101;&#112;&#114;&#105;&#118;&#097;&#116;&#101;&#101;&#113;&#117;&#105;&#116;&#101;&#101;&#114;&#046;&#099;&#111;&#109;">Email</a></li>
    </ul>
</aside>
<!-- END UPDATE -->

<footer>&copy; The Private Equiteer</footer>

<script>
(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,'script','https://www.google-analytics.com/analytics.js','ga');
ga('create', 'UA-5371517-4', 'auto');
ga('send', 'pageview');
</script>

</body>

</html>
